Importantly, Kaplan–Meier analysis indicated that HER2+ BC patients with higher expression of circCDYL exhibited a poorer disease-free survival (DFS) (HR = 6.327, P = 0.0178) (Figure 6C). This evidence concerns the gene ERBB2 and breast cancer.